Waist circumference is a better predictor of cardiovascular risk than body mass index in patients…

This is an automatically generated default intro template – please do not edit.

	Read full article
Article Title:	Waist circumference is a better predictor of cardiovascular risk than body mass index in patients with metabolic syndrome
Authors:	Laura Petrica
Affiliation:	Cardiology Clinic ASCAR, City Hospital Timisoara, Romania
Abstract:	Background and aim. Waist circumference and body mass index represent diagnostic elements in different definitions of metabolic syndrome. The aim of this work was to establish which one of these parameters correlates better with cardiovascular risk in subjects with metabolic syndrome. Material and method. The study group was represented by 383 subjects with metabolic syndrome, 41% male, mean age ± SD=54.2±13.6 years. The cardiovascular risk was estimated with the aid of SCORE charts for high risk populations. The threshold for statistical significance for p was 0.05. Results. Cardiovascular risk was higher in men than in women (4.9±4.4% vs. 3.7±3.5%, p=0.003) and increased extremely significant with age (p <0.001). There was a correlation between cardiovascular risk and body mass index (r=0.57). The correlation was stronger between cardiovascular risk and abdominal circumference, both in men (r=0.66) and in women (r=0.69). Conclusion. Abdominal circumference is a better predictor for cardiovascular events than body mass index in persons with metabolic syndrome.
Keywords:	waist circumference, cardiovascular risk, body mass index, metabolic syndrome
References:	Hu G, Qiao Q, Tuomilehto J et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076. Kahn R, Buse J, Ferrannini E et al. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304. Kuk JL, Katzmarzyk PT, Nichaman MZ et al. Visceral fat is an independent predictor of all-cause mortality in men. Obes Res 2006; 14: 336-341. Wilson PW, D’Agostino RB, Parise H. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553. Sundström J, Risérus U, Byberg L et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878-882. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421. Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-252. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: 1059-1062. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): E1-E40. Rigo F, Frontera J, Llobera J, et al. Prevalence of cardiovascular risk factors in the Balearic Islands (CORSAIB Study). Rev Esp Cardiol 2005; 58: 1411-1419. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825. Wilson PW. Adiposity in youth and blood pressure. Hypertension 2006; 48: 21-22. Study rationale and design of ADVANCE. Action in Diabetes and Vascular Disease – Preterax and Diamicron MR Controlled Evaluation. Diabetologia 2001; 44: 1118-1120.
*Correspondence:	Laura Petrica, Cardiology Clinic ASCAR, City Hospital Timisoara, Romania E-mail: petricalaura@yahoo.com